PortalPublikationenShould anti-thymocyte globulin be added in post-transplant c...

Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT

Standard

Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. / Spyridonidis, Alexandros; Labopin, Myriam; Brissot, Eolia; Moiseev, Ivan; Cornelissen, Jan; Choi, Goda; Ciceri, Fabio; Vydra, Jan; Reményi, Péter; Rovira, Montserrat; Meijer, Ellen; Labussière-Wallet, Hélène; Blaise, Didier; van Gorkom, Gwendolyn; Kröger, Nicolaus; Koc, Yener; Giebel, Sebastian; Bazarbachi, Ali; Savani, Bipin; Nagler, Arnon; Mohty, Mohamad.

in: BONE MARROW TRANSPL, Jahrgang 57, Nr. 12, 12.2022, S. 1774-1780.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Spyridonidis, A, Labopin, M, Brissot, E, Moiseev, I, Cornelissen, J, Choi, G, Ciceri, F, Vydra, J, Reményi, P, Rovira, M, Meijer, E, Labussière-Wallet, H, Blaise, D, van Gorkom, G, Kröger, N, Koc, Y, Giebel, S, Bazarbachi, A, Savani, B, Nagler, A & Mohty, M 2022, 'Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT', BONE MARROW TRANSPL, Jg. 57, Nr. 12, S. 1774-1780. https://doi.org/10.1038/s41409-022-01816-1

APA

Spyridonidis, A., Labopin, M., Brissot, E., Moiseev, I., Cornelissen, J., Choi, G., Ciceri, F., Vydra, J., Reményi, P., Rovira, M., Meijer, E., Labussière-Wallet, H., Blaise, D., van Gorkom, G., Kröger, N., Koc, Y., Giebel, S., Bazarbachi, A., Savani, B., ... Mohty, M. (2022). Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. BONE MARROW TRANSPL, 57(12), 1774-1780. https://doi.org/10.1038/s41409-022-01816-1

Vancouver

Spyridonidis A, Labopin M, Brissot E, Moiseev I, Cornelissen J, Choi G et al. Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. BONE MARROW TRANSPL. 2022 Dez;57(12):1774-1780. https://doi.org/10.1038/s41409-022-01816-1

Bibtex

@article{686c85f1345a485286dce86e90cbf502,
title = "Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT",
abstract = "In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and received post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GvHD) prophylaxis, we compared 421 recipients without anti-thymocyte globulin (ATG) with 151 patients with ATG. The only significant differences between PTCY and PTCY + ATG cohorts were the median year of transplant and the follow-up period (2017 vs 2015 and 19.6 vs 31.1 months, respectively, p < 0.0001). Overall, 2-year survival was 69.9% vs 67.1% in PTCY and PTCY + ATG, respectively, with deaths related to relapse (39% vs 43.5%), infection (21.9% vs 23.9%) or GvHD (17.1% vs 17.4%) not differing between groups. On univariate comparison, a significantly lower rate of extensive chronic GvHD was found when ATG was added (9.9% vs 21%, p = 0.029), a finding which was not confirmed in the multivariate analysis. The Cox-model showed no difference between PTCY + ATG and PTCY alone with respect to acute and chronic GvHD of all grades, non-relapse mortality, relapse, leukemia-free survival, overall survival, and GvHD-free-relapse-free survival between study cohorts. Our results highlight that the addition of ATG in PTCY does not provide any extra benefit in terms of further GvHD reduction, better GRFS or better survival.",
keywords = "Humans, Antilymphocyte Serum/therapeutic use, Peripheral Blood Stem Cell Transplantation/methods, Unrelated Donors, Graft vs Host Disease, Cyclophosphamide/therapeutic use, Hematopoietic Stem Cell Transplantation/methods, Leukemia, Myeloid, Acute/drug therapy, Recurrence, Retrospective Studies",
author = "Alexandros Spyridonidis and Myriam Labopin and Eolia Brissot and Ivan Moiseev and Jan Cornelissen and Goda Choi and Fabio Ciceri and Jan Vydra and P{\'e}ter Rem{\'e}nyi and Montserrat Rovira and Ellen Meijer and H{\'e}l{\`e}ne Labussi{\`e}re-Wallet and Didier Blaise and {van Gorkom}, Gwendolyn and Nicolaus Kr{\"o}ger and Yener Koc and Sebastian Giebel and Ali Bazarbachi and Bipin Savani and Arnon Nagler and Mohamad Mohty",
note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
month = dec,
doi = "10.1038/s41409-022-01816-1",
language = "English",
volume = "57",
pages = "1774--1780",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT

AU - Spyridonidis, Alexandros

AU - Labopin, Myriam

AU - Brissot, Eolia

AU - Moiseev, Ivan

AU - Cornelissen, Jan

AU - Choi, Goda

AU - Ciceri, Fabio

AU - Vydra, Jan

AU - Reményi, Péter

AU - Rovira, Montserrat

AU - Meijer, Ellen

AU - Labussière-Wallet, Hélène

AU - Blaise, Didier

AU - van Gorkom, Gwendolyn

AU - Kröger, Nicolaus

AU - Koc, Yener

AU - Giebel, Sebastian

AU - Bazarbachi, Ali

AU - Savani, Bipin

AU - Nagler, Arnon

AU - Mohty, Mohamad

N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022/12

Y1 - 2022/12

N2 - In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and received post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GvHD) prophylaxis, we compared 421 recipients without anti-thymocyte globulin (ATG) with 151 patients with ATG. The only significant differences between PTCY and PTCY + ATG cohorts were the median year of transplant and the follow-up period (2017 vs 2015 and 19.6 vs 31.1 months, respectively, p < 0.0001). Overall, 2-year survival was 69.9% vs 67.1% in PTCY and PTCY + ATG, respectively, with deaths related to relapse (39% vs 43.5%), infection (21.9% vs 23.9%) or GvHD (17.1% vs 17.4%) not differing between groups. On univariate comparison, a significantly lower rate of extensive chronic GvHD was found when ATG was added (9.9% vs 21%, p = 0.029), a finding which was not confirmed in the multivariate analysis. The Cox-model showed no difference between PTCY + ATG and PTCY alone with respect to acute and chronic GvHD of all grades, non-relapse mortality, relapse, leukemia-free survival, overall survival, and GvHD-free-relapse-free survival between study cohorts. Our results highlight that the addition of ATG in PTCY does not provide any extra benefit in terms of further GvHD reduction, better GRFS or better survival.

AB - In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and received post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GvHD) prophylaxis, we compared 421 recipients without anti-thymocyte globulin (ATG) with 151 patients with ATG. The only significant differences between PTCY and PTCY + ATG cohorts were the median year of transplant and the follow-up period (2017 vs 2015 and 19.6 vs 31.1 months, respectively, p < 0.0001). Overall, 2-year survival was 69.9% vs 67.1% in PTCY and PTCY + ATG, respectively, with deaths related to relapse (39% vs 43.5%), infection (21.9% vs 23.9%) or GvHD (17.1% vs 17.4%) not differing between groups. On univariate comparison, a significantly lower rate of extensive chronic GvHD was found when ATG was added (9.9% vs 21%, p = 0.029), a finding which was not confirmed in the multivariate analysis. The Cox-model showed no difference between PTCY + ATG and PTCY alone with respect to acute and chronic GvHD of all grades, non-relapse mortality, relapse, leukemia-free survival, overall survival, and GvHD-free-relapse-free survival between study cohorts. Our results highlight that the addition of ATG in PTCY does not provide any extra benefit in terms of further GvHD reduction, better GRFS or better survival.

KW - Humans

KW - Antilymphocyte Serum/therapeutic use

KW - Peripheral Blood Stem Cell Transplantation/methods

KW - Unrelated Donors

KW - Graft vs Host Disease

KW - Cyclophosphamide/therapeutic use

KW - Hematopoietic Stem Cell Transplantation/methods

KW - Leukemia, Myeloid, Acute/drug therapy

KW - Recurrence

KW - Retrospective Studies

U2 - 10.1038/s41409-022-01816-1

DO - 10.1038/s41409-022-01816-1

M3 - SCORING: Journal article

C2 - 36071114

VL - 57

SP - 1774

EP - 1780

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 12

ER -